Gevorg Yaghjyan/LinkedIn
Apr 2, 2026, 15:52
Gevorg Yaghjyan: How Yale is Redefining Bladder Cancer Treatment Through Strategy Focused Trials
Gevorg Yaghjyan, Former Project Leader at Parexel, shared a post on LinkedIn:
“Clinical trials are evolving from testing drugs to testing strategies.
A new study from Yale School of Medicine in metastatic bladder cancer highlights this shift:
- Systemic therapy (ADC plus immunotherapy)
- Response-based patient selection
- Consolidative surgery in responders
This is not a traditional trial.
It’s a multimodal, adaptive treatment pathway.
From a clinical development perspective, key takeaways:
- Dynamic, response – driven enrollment
- Integration of medical plus surgical oncology
- Increasing operational complexity at site level
- Movement toward strategy – based endpoints
This is where oncology trials are heading:
From molecule-focused – to patient pathway – focused design”
Stay updated with Hemostasis Today.
-
Jun 4, 2026, 05:30Raghavendra Rao: Early Endothermal Ablation and Contemporary Management of Superficial Venous Thrombosis
-
Jun 4, 2026, 05:18Fouad Mikhail: Mechanical Thrombectomy and Anticoagulation in Intermediate-Risk Pulmonary Embolism
-
Jun 3, 2026, 17:18Giacomo Rossi: Cysteine and Gut Health – MIT Finds the Switch
-
Jun 3, 2026, 17:00Amin Ullah: Presence of RBCs of Unequal Sizes in a Peripheral Blood Smear – Anisocytosis of RBC
-
Jun 3, 2026, 16:59Jean Connors: Discussing Cancer-Associated Thrombosis at the Japanese Society of Thrombosis and Hemostasis
-
Jun 3, 2026, 16:54Ayush Bhowmik: Failed Drug Became the World’s Most Widely Used Blood Thinner
-
Jun 3, 2026, 16:13Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
-
Jun 3, 2026, 16:08Pedro Henrique Las Casas: How Anticoagulant Agents and Quercetin Influence Cancer Cell Procoagulant Activity
-
Jun 3, 2026, 16:07Suraj Wilson: Back From ASCO 2026 With A Renewed Commitment To Cancer Research